We are analyzing https://link.springer.com/article/10.1007/s10637-010-9408-4.

Title:
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium | Investigational New Drugs
Description:
Background Sorafenib is an oral multikinase inhibitor that blocks cell proliferation via the ERK pathway and angiogenesis via the VEGF pathway. This phase II trial was conducted to determine the efficacy and tolerability of sorafenib for the treatment of patients with metastatic urothelial cancer (UC) who had not had prior chemotherapy for advanced disease. Patients and Methods Seventeen chemo-naïve UC patients with adequate performance status and organ function were treated with sorafenib 400 mg twice daily on a continuous basis until progression or unacceptable toxicity. The primary endpoint was objective tumor response rate as measured by RECIST criteria. Secondary endpoints included rate of prolonged stable disease (>3 months), time to progression, median and 1 yr survival and safety and tolerability. Results There were no objective responses. Only one patient had stable disease by RECIST criteria and remained on treatment more than 3 months. Three patients had stable disease by RECIST criteria but were on treatment less than 3 months due to progressive disease (PD) or adverse events (AE). Eight patients had PD by RECIST criteria as their best overall response. Two patients had symptomatic PD prior to cycle 2 evaluation, and three patients were inevaluable (1 death, 1 AE, 1 withdrew consent).The time to progression was 1.9 months (range 0.7–8.7 months) and median survival was 5.9 months. The most common grade 3+ toxicities were abdominal pain, back pain, hand-foot reaction and bladder infection. Conclusions Sorafenib does not show sufficient activity as a single agent in first-line metastatic urothelial cancer to warrant further investigation.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, article, pubmed, google, scholar, cas, phase, sorafenib, patients, urothelial, advanced, study, bladder, metastatic, carcinoma, clin, oncol, trial, treatment, progression, months, privacy, cookies, content, sridhar, disease, access, gemcitabine, information, journal, publish, search, firstline, eisen, moore, recist, criteria, res, schwartz, human, growth, canada, data, log, research, drugs, consortium, february, srikala, winquist,

Topics {✒️}

month download article/chapter metastatic transitional-cell carcinoma phase ii consortium phase ii trial n-ras proto-oncogenes national cancer institute human urothelial carcinoma phase ii study raf/mek/erk pathway metastatic urothelial cancer advanced urothelial cancer full article pdf human bladder tumors refractory urothelial carcinoma cisplatin-based chemotherapy advanced hepatocellular carcinoma privacy choices/manage cookies oral multikinase inhibitor metastatic bladder cancer blocks cell proliferation phase iii study targeted agents genitourinary cancers symposium vegf receptor expression urinary bladder cancer superficial bladder cancer phase 2 trial invasive bladder cancer show sufficient activity anti-angiogenic therapy prior chemotherapy european economic area adequate performance status hand-foot reaction hill-harmon mb ras superfamily proteins copy number alterations clinical oncology lara pn jr article investigational conditions privacy policy visseren-grul cm de oliveira ac continuous dosing schedule bladder cancer progression moore mj long-term survival accepting optional cookies cisplatin versus methotrexate stadler wm

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
         description:Background Sorafenib is an oral multikinase inhibitor that blocks cell proliferation via the ERK pathway and angiogenesis via the VEGF pathway. This phase II trial was conducted to determine the efficacy and tolerability of sorafenib for the treatment of patients with metastatic urothelial cancer (UC) who had not had prior chemotherapy for advanced disease. Patients and Methods Seventeen chemo-naïve UC patients with adequate performance status and organ function were treated with sorafenib 400 mg twice daily on a continuous basis until progression or unacceptable toxicity. The primary endpoint was objective tumor response rate as measured by RECIST criteria. Secondary endpoints included rate of prolonged stable disease (>3 months), time to progression, median and 1 yr survival and safety and tolerability. Results There were no objective responses. Only one patient had stable disease by RECIST criteria and remained on treatment more than 3 months. Three patients had stable disease by RECIST criteria but were on treatment less than 3 months due to progressive disease (PD) or adverse events (AE). Eight patients had PD by RECIST criteria as their best overall response. Two patients had symptomatic PD prior to cycle 2 evaluation, and three patients were inevaluable (1 death, 1 AE, 1 withdrew consent).The time to progression was 1.9 months (range 0.7–8.7 months) and median survival was 5.9 months. The most common grade 3+ toxicities were abdominal pain, back pain, hand-foot reaction and bladder infection. Conclusions Sorafenib does not show sufficient activity as a single agent in first-line metastatic urothelial cancer to warrant further investigation.
         datePublished:2010-02-27T00:00:00Z
         dateModified:2010-02-27T00:00:00Z
         pageStart:1045
         pageEnd:1049
         sameAs:https://doi.org/10.1007/s10637-010-9408-4
         keywords:
            Sorafenib
            Metastatic urothelial cancer
            Phase II
            First-line
            Oncology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Investigational New Drugs
            issn:
               1573-0646
               0167-6997
            volumeNumber:29
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Srikala S. Sridhar
               affiliation:
                     name:Princess Margaret Hospital, Phase II Consortium
                     address:
                        name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Eric Winquist
               affiliation:
                     name:London Regional Cancer Center
                     address:
                        name:London Regional Cancer Center, London, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrea Eisen
               affiliation:
                     name:Odette Cancer Center
                     address:
                        name:Odette Cancer Center, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sebastien J. Hotte
               affiliation:
                     name:Juravinski Cancer Center
                     address:
                        name:Juravinski Cancer Center, Hamilton, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elaine McWhirter
               affiliation:
                     name:Juravinski Cancer Center
                     address:
                        name:Juravinski Cancer Center, Hamilton, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ian F. Tannock
               affiliation:
                     name:Princess Margaret Hospital, Phase II Consortium
                     address:
                        name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Som D. Mukherjee
               affiliation:
                     name:Juravinski Cancer Center
                     address:
                        name:Juravinski Cancer Center, Hamilton, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lisa Wang
               affiliation:
                     name:Princess Margaret Hospital, Phase II Consortium
                     address:
                        name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chantale Blattler
               affiliation:
                     name:Princess Margaret Hospital, Phase II Consortium
                     address:
                        name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John J. Wright
               affiliation:
                     name:Cancer Therapy Evaluation Program, National Cancer Institute
                     address:
                        name:Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Malcolm J. Moore
               affiliation:
                     name:Princess Margaret Hospital, Phase II Consortium
                     address:
                        name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
      description:Background Sorafenib is an oral multikinase inhibitor that blocks cell proliferation via the ERK pathway and angiogenesis via the VEGF pathway. This phase II trial was conducted to determine the efficacy and tolerability of sorafenib for the treatment of patients with metastatic urothelial cancer (UC) who had not had prior chemotherapy for advanced disease. Patients and Methods Seventeen chemo-naïve UC patients with adequate performance status and organ function were treated with sorafenib 400 mg twice daily on a continuous basis until progression or unacceptable toxicity. The primary endpoint was objective tumor response rate as measured by RECIST criteria. Secondary endpoints included rate of prolonged stable disease (>3 months), time to progression, median and 1 yr survival and safety and tolerability. Results There were no objective responses. Only one patient had stable disease by RECIST criteria and remained on treatment more than 3 months. Three patients had stable disease by RECIST criteria but were on treatment less than 3 months due to progressive disease (PD) or adverse events (AE). Eight patients had PD by RECIST criteria as their best overall response. Two patients had symptomatic PD prior to cycle 2 evaluation, and three patients were inevaluable (1 death, 1 AE, 1 withdrew consent).The time to progression was 1.9 months (range 0.7–8.7 months) and median survival was 5.9 months. The most common grade 3+ toxicities were abdominal pain, back pain, hand-foot reaction and bladder infection. Conclusions Sorafenib does not show sufficient activity as a single agent in first-line metastatic urothelial cancer to warrant further investigation.
      datePublished:2010-02-27T00:00:00Z
      dateModified:2010-02-27T00:00:00Z
      pageStart:1045
      pageEnd:1049
      sameAs:https://doi.org/10.1007/s10637-010-9408-4
      keywords:
         Sorafenib
         Metastatic urothelial cancer
         Phase II
         First-line
         Oncology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Investigational New Drugs
         issn:
            1573-0646
            0167-6997
         volumeNumber:29
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Srikala S. Sridhar
            affiliation:
                  name:Princess Margaret Hospital, Phase II Consortium
                  address:
                     name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Eric Winquist
            affiliation:
                  name:London Regional Cancer Center
                  address:
                     name:London Regional Cancer Center, London, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrea Eisen
            affiliation:
                  name:Odette Cancer Center
                  address:
                     name:Odette Cancer Center, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sebastien J. Hotte
            affiliation:
                  name:Juravinski Cancer Center
                  address:
                     name:Juravinski Cancer Center, Hamilton, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elaine McWhirter
            affiliation:
                  name:Juravinski Cancer Center
                  address:
                     name:Juravinski Cancer Center, Hamilton, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ian F. Tannock
            affiliation:
                  name:Princess Margaret Hospital, Phase II Consortium
                  address:
                     name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Som D. Mukherjee
            affiliation:
                  name:Juravinski Cancer Center
                  address:
                     name:Juravinski Cancer Center, Hamilton, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lisa Wang
            affiliation:
                  name:Princess Margaret Hospital, Phase II Consortium
                  address:
                     name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chantale Blattler
            affiliation:
                  name:Princess Margaret Hospital, Phase II Consortium
                  address:
                     name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John J. Wright
            affiliation:
                  name:Cancer Therapy Evaluation Program, National Cancer Institute
                  address:
                     name:Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Malcolm J. Moore
            affiliation:
                  name:Princess Margaret Hospital, Phase II Consortium
                  address:
                     name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Investigational New Drugs
      issn:
         1573-0646
         0167-6997
      volumeNumber:29
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Princess Margaret Hospital, Phase II Consortium
      address:
         name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
         type:PostalAddress
      name:London Regional Cancer Center
      address:
         name:London Regional Cancer Center, London, Canada
         type:PostalAddress
      name:Odette Cancer Center
      address:
         name:Odette Cancer Center, Toronto, Canada
         type:PostalAddress
      name:Juravinski Cancer Center
      address:
         name:Juravinski Cancer Center, Hamilton, Canada
         type:PostalAddress
      name:Juravinski Cancer Center
      address:
         name:Juravinski Cancer Center, Hamilton, Canada
         type:PostalAddress
      name:Princess Margaret Hospital, Phase II Consortium
      address:
         name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
         type:PostalAddress
      name:Juravinski Cancer Center
      address:
         name:Juravinski Cancer Center, Hamilton, Canada
         type:PostalAddress
      name:Princess Margaret Hospital, Phase II Consortium
      address:
         name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
         type:PostalAddress
      name:Princess Margaret Hospital, Phase II Consortium
      address:
         name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
         type:PostalAddress
      name:Cancer Therapy Evaluation Program, National Cancer Institute
      address:
         name:Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA
         type:PostalAddress
      name:Princess Margaret Hospital, Phase II Consortium
      address:
         name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Srikala S. Sridhar
      affiliation:
            name:Princess Margaret Hospital, Phase II Consortium
            address:
               name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Eric Winquist
      affiliation:
            name:London Regional Cancer Center
            address:
               name:London Regional Cancer Center, London, Canada
               type:PostalAddress
            type:Organization
      name:Andrea Eisen
      affiliation:
            name:Odette Cancer Center
            address:
               name:Odette Cancer Center, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Sebastien J. Hotte
      affiliation:
            name:Juravinski Cancer Center
            address:
               name:Juravinski Cancer Center, Hamilton, Canada
               type:PostalAddress
            type:Organization
      name:Elaine McWhirter
      affiliation:
            name:Juravinski Cancer Center
            address:
               name:Juravinski Cancer Center, Hamilton, Canada
               type:PostalAddress
            type:Organization
      name:Ian F. Tannock
      affiliation:
            name:Princess Margaret Hospital, Phase II Consortium
            address:
               name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Som D. Mukherjee
      affiliation:
            name:Juravinski Cancer Center
            address:
               name:Juravinski Cancer Center, Hamilton, Canada
               type:PostalAddress
            type:Organization
      name:Lisa Wang
      affiliation:
            name:Princess Margaret Hospital, Phase II Consortium
            address:
               name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Chantale Blattler
      affiliation:
            name:Princess Margaret Hospital, Phase II Consortium
            address:
               name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:John J. Wright
      affiliation:
            name:Cancer Therapy Evaluation Program, National Cancer Institute
            address:
               name:Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Malcolm J. Moore
      affiliation:
            name:Princess Margaret Hospital, Phase II Consortium
            address:
               name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
      name:London Regional Cancer Center, London, Canada
      name:Odette Cancer Center, Toronto, Canada
      name:Juravinski Cancer Center, Hamilton, Canada
      name:Juravinski Cancer Center, Hamilton, Canada
      name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
      name:Juravinski Cancer Center, Hamilton, Canada
      name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
      name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
      name:Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA
      name:Princess Margaret Hospital, Phase II Consortium, Toronto, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(108)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.1s.

LINK . SPRINGER . COM {}